Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection

Abstract

We report a 55-year-old male who developed advanced hepatic metastasis and peritoneal carcinomatosis after resection of remnant gastric cancer resection 3 mo ago. The patient only received epidermal growth factor (EGF) receptor antibody (Cetuximab) plus recombinant human endostatin (Endostar). Anti-tumor activity was assessed by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computer tomography (PET/CT) at baseline and then every 4 wk. The case illustrates that (18)FDG-PET/CT could make an early prediction of the response to Cetuximab plus Endostar in such clinical situations. (18)FDG-PET/CT is a useful molecular imaging modality to evaluate the biological response advanced hepatic metastasis and peritoneal carcinomatosis to Cetuximab plus Endostar in patients after remnant gastric cancer resection.

Figures

Figure 1

Base line FDG PET/CT detecting a highly metabolic metastasis in liver (white arrows, A and B), second FDG PET/CT demonstrating the decreased number and metabolism level of liver metastases and one highly metabolic metastasis in the left lobe of liver (white arrows, C and D), third FDG PET/CT displaying no lesion at the same position (E and F).

Figure 2

Base line FDG PET/CT detecting huge metastases in the right lobe of liver and highly metastatic lymphoid nodes in abdomen (white arrows, A and B), second FDG PET/CT demonstrating huge metastases in the right lobe of liver and the decreased number, size and metabolism level of metastatic lymphoid nodes (white arrows, C and D), third FDG PET/CT displaying the disappeared huge metastases in the right lobe of liver and the normal size of metastatic lymphoid nodes (E and F).

Figure 3

Base line FDG PET/CT detecting multi high metastases in both lobes of liver and highly metastatic lymphoid nodes in abdomen (white arrows, A and B), second FDG PET/CT demonstrating multi high metastases in the liver and the decreased number, size and metabolism level of metastatic lymphoid nodes (white arrows, C and D), third FDG PET/CT displaying disappeared liver metastasis and metastatic lymphoid nodes (E and F).